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SummAry
in spite of the amount of literature demonstrating the relationship between upper and lower airways, both from the anatomical, and patho-
physiological point of view, little is known about the epidemiology, diagnosis and treatment of the rhino-Bronchial Syndrome (rBS). After 
the publication, in 2003, of a Consensus report defining the rhino-Bronchial Syndrome, an interdisciplinary group of experts made up 
from the italian EnT Society (Sio) and the interdisciplinary Scientific Association for the Study of respiratory Diseases (AimAr) met 
again in 2005 in order to study a protocol which would have, as the main tasks, the analysis of rBS signs and symptoms and standardiza-
tion of the diagnostic approach. A secondary endpoint was to characterize the most effective therapeutic options and to correct the great 
dyshomogeneity in the therapeutic approaches. With this aim, 9 EnT and Pneumology Centres were selected, based on the ability to multi-
disciplinary cooperation, availability of useful instrumentation and homogeneous distribution over the entire national territory. overall, 
159 patients were enrolled according to clinical history (major and minor symptoms of upper and lower airways) and inclusion/exclusion 
criteria. All underwent a two level diagnostic approach. in 116 patients, the diagnosis was confirmed on the basis of i level (rhinopharyngeal 
endoscopy and basal spirometry, respectively, for upper and lower airways) examination. Allergic and infectious diseases were significantly 
more frequent (37.9% vs 20.9% and 73.3% vs 46.55, respectively) in patients with a confirmed diagnosis for rhino-Bronchial Syndrome. 
nasal obstruction (93%), rhinorrhoea (75%), cough (96%) and dyspnoea (69%) were the more frequent symptoms. The presence of meatal 
secretions or polyps were the clinical findings significantly differing at endoscopy in the two groups. After 3 months of treatment, according 
to “good clinical practice” (inhaled steroids, antibiotics, nasal lavages), 96% of the patients recovered. on the basis of these results, a diag-
nostic flow-chart is proposed according to which the persistence of some symptoms (cough, dyspnoea, rhinorrhoea and nasal obstruction) 
should lead the patient to a multidisciplinary and multi-level diagnostic approach by an otorhinolaryngology and a pneumology specialist 
working together for a definitive diagnosis. The recovery rate of about 94% of patients after 3 months of treatment, stresses the importance 
of a correct diagnosis.
KEy WorDS: Upper and lower airways • Rhino-Bronchial Syndrome • Inflammatory cytokines • Rhino-bronchial reflex • Diagnosis • 
Treatment
riASSunTo
Nonostante le numerose ricerche rinvenibili in letteratura a sostegno di una correlazione anatomica e fisiopatologia fra alte e basse vie 
aeree, poco si sa dell’epidemiologia, della diagnosi e del trattamento della Sindrome Rino-Bronchiale (SRB). Dopo la pubblicazione nel 
2003 di una Consensus per la definizione della Sindrome Rino-Bronchiale, un gruppo multidisciplinare di esperti composto da rappresen-
tanti della SIO (Società Italiana di Otorinolaringologia e Chirurgia Cervico-Facciale) e dell’AIMAR (Associazione Interdisciplinare per 
lo studio delle Malattie Respiratorie), si è riunito nuovamente nel 2005 con l’intento di mettere a punto un protocollo di studio avente come 
obiettivi principali l’analisi dei segni e sintomi della Sindrome Rino-Bronchiale e la standardizzazione dell’approccio diagnostico. Obietti-
vo secondario del protocollo era l’individuazione delle opzioni terapeutiche più efficaci per correggere l’elevata disomogeneità a tutt’oggi 
presente nel trattamento della sindrome. In quest’ottica sono stati selezionati 9 centri distribuiti su tutto il territorio nazionale che avessero 
la possibilità di una collaborazione interdisciplinare e fossero forniti di necessaria strumentazione. Sulla base della storia clinica (segni D. Passali et al.
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e sintomi maggiori e minori a carico delle vie aeree superiori ed inferiori) e dei criteri di inclusione ed esclusione, sono stati arruolati 
159 pazienti. In 116, la diagnosi di Sindrome Rino-Bronchiale è stata confermata sulla base di un protocollo diagnostico che prevedeva 
indagini di I (endoscopia rinofaringea e spirometria basale rispettivamente per le vie aeree superiori ed inferiori) e II livello. Le patolo-
gie infiammatorie ed infettive erano significativamente più frequenti nei soggetti con diagnosi di Sindrome Rino-Bronchiale confermata 
(37,9% vs 20,9% e 73,3% vs 46,55% rispettivamente). L’ostruzione nasale (93%), la rinorrea (75%), la tosse (96%) e la dispnea (69%) 
sono stati i sintomi più frequentemente rilevati. La presenza di secrezioni in corrispondenza dell’ostio-meato e/o di polipi all’indagine 
endoscopica differiva significativamente nei due gruppi (diagnosi confermata o no). Al termine di 3 mesi di trattamento seguendo i criteri 
della “buona pratica clinica” (cortisonici per aerosol, antibiotici, lavande nasali) la risoluzione della sintomatologia è stata rilevata nel 
96% dei pazienti. Sulla base dei risultati gli Autori propongono una flow-chart diagnostica che preveda un approccio integrato e multili-
vello tra specialisti delle vie aeree superiori ed inferiori in caso di presenza e persistenza di tosse, dispnea, ostruzione nasale, rinorrea. La 
risoluzione della sintomatologia nel 94% dei pazienti dopo tre mesi di terapia, sottolinea l’importanza di un corretto approccio diagnostico 
quale premessa alla terapia.
PArolE ChiAvE: Vie aeree superiori e inferiori • Sindrome Rino-Bronchiale • Citochine infiammatorie • Riflesso rino-bronchiale • 
Diagnosi • Terapia
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Introduction
various  studies  have  demonstrated  that  the  upper  and 
lower airways have not only an anatomical continuity, but 
adopt, also, the same physiopathological mechanisms in 
order to answer pathogenic noxae; therefore they must be 
considered as a unique morphofunctional unit.
The key pathogenic mechanism is the inflammation of the 
upper airways no matter how it was induced, which is able 
to extend to the lower airways inducing also a systemic 
deregulation, with a complex interaction between cells 
and inflammatory cytokines.
But, if it is, by now, true that a lot that we know with re-
gard to the pathogenetic mechanisms that relate upper and 
lower airways 1-7, little, on the contrary, is known about the 
epidemiology, the diagnostic approach and the therapeu-
tic behaviour to be adopted in clinical pictures involving 
these two districts.
in particular, as far as concerns the pathogenesis, rhino-
bronchial reflex 8 9 is one of the mechanisms able to ex-
plain the upper-lower airways relationship, even if the 
exact anatomical location of the afferent branch of this 
reflex has not yet been clearly defined. namely, applica-
tion, on the nasal mucosa, of a stimulus such an allergen 
or (in some cases) just cold air, is able to determine an 
immediate broncho-spasm. moreover, we must remember 
the role of descending infections (post-nasal drip): falling 
of inflammatory material (mucous-pus and inflammatory 
cells) from the upper airways towards the lower district, 
inhaled because of the inspiratory activity of the lungs, 
could represent an important irritating trigger 10 11.
last, but not least, a third extremely important direct 
pathogenetic mechanism is represented by the diffuse 
mucosal  inflammation,  caused  by  activation  of  eosi-
nophils. According to this hypothesis, any inflammation 
in the upper airways (independently of the origin: aller-
gic, infective or irritative) is a fundamental prodromic 
event for the extension of the pathology to the lower air-
ways.
Specifically, eosinophils, through the release of specific 
mediators,  such  as  ECP  (Eosinophil  Cationic  Protein), 
EPo (Eosinophil Peroxidase), mPo (myeloperoxidase) 
or nmP (nitrate-methyl-Proxyl), potent no-donor (nitric 
oxide-donor) involved in all the oxidative stress-mediated 
pathologies, seem to be able to induce diffuse mucosal 
damage throughout the entire respiratory tree 12.
The  Consensus  report  on  the  rhino-Bronchial  Syn-
drome, processed in 2003 by the interdisciplinary group 
of the italian otorhinolaryngology Society (Sio) and the 
interdisciplinary Association for the Study of the respi-
ratory Diseases (AimAr) defined the rhino-Bronchial 
Syndrome (rBS) as “a nosologic entity which develops 
when a hyper-reactive process or a recurrent or chronic 
inflammation of the upper airways, or anatomical altera-
tions of the rhinosinusal district, facilitate the develop-
ment of an inflammatory state, on an infectious or immu-
nological basis, in the lower airways, compromising also 
their function” 13.
in this context, a Scientific Committee, made up of ex-
perts from the two Societies, has attempted to define a 
study protocol which had, as the main task, to analyze 
signs and symptoms of rBS and to standardize the diag-
nostic approach, defining the first and second level exami-
nations to be performed.
The secondary endpoint of the study was to characterize, 
between the various therapeutic options, those most effec-
tive, thus contributing, to correct the great dishomogene-
ity, in the therapeutic approaches, currently proposed.
Materials and methods
in 2005, 9 EnT and Pneumology Centres were identified 
(Fig. 1) and selected, based on the following requirements: 
ability  to  multidisciplinary  cooperation,  availability  of 
useful  instrumentations  for  the  study  and  homogenous 
distribution over the entire national territory.
After a meeting of investigators to define the sharing of 
the protocol and after submission of the same for approval Sio-AimAr survey on rhino-Bronchial Syndrome
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of the Ethics Committee of the Coordinating Centre, it 
was agreed, starting from 1.1.2006, to start the enrollment 
of all the subjects who, in the course of the year consecu-
tively, referred to the outpatient departments (every pa-
tient had to be estimated by both the specialists) and who 
met the following inclusion criteria:
•  males and females aged between 18 and 70 years;
•  typical symptoms:
a) presence of at least one major criterion for both up-
per and lower airways;
b) presence of one major criterion for lower airways 
and 2 minor criteria for upper airways.
Major Criteria:  upper airways: nasal obstruction, post-
nasal drip, cough. lower airways: cough, dyspnoea, spu-
tum.
Minor  Criteria:  rhinorrhoea,  itching,  anosmia,  sore 
throat, facial pain, nose bleeding, fever.
Exclusion criteria were:
•  patients submitted, in the last 3 months, to upper or 
lower airways surgical procedures;
•  patients with active oncologic conditions;
•  patients with heart failure (NYHA class II or above);
•  patients taking ACE-inhibitors;
•  recent or ongoing pneumonia (2 months);
•  patients with TBC;
•  immunocompromised patients;
•  HIV patients;
•  pregnant women;
•  patients with genetic disorders.
All clinical data, collected in the various centres, were 
stored on an on-line database for the statistical analysis. 
Each patient, enrolled according to clinical history and 
inclusion criteria, underwent a two-level diagnostic ap-
proach, as shown in Tables i and ii. All the investigations 
were performed within 4 months from the enrollment.
After enrollment of patients, the clinical diagnosis was 
confirmed,  or  excluded,  according  to  the  examinations 
defined  by  the  “2003  Sio-AimAr  Consensus  report” 
and the patients were treated according to the “good clini-
cal  practice”  by  the  enrolling  specialists.  Specifically, 
concerning upper airway disorders, when chronic rhino-
sinusitis was diagnosed, on the basis of symptoms (nasal 
obstruction, secretion) and signs (mucosal hypertrophy, 
secretion at the ostio-meatal complex) by nasal endos-
copy and/or CT scan, topical steroids (mometasone furo-
ate, fluticasone proprionate and fluticasone furoate) were 
used on alternate months for 3 months (200 or 400 μg/
day according to the severity of the clinical picture). This 
treatment regimen was not changed when nasal polyps, 
confined to the middle meatus were present. nasal lavag-
es/douching with isotonic solution were suggested, once 
or more times/day, to all the patients. oral anti-histamines 
or  leukotrienes  antagonist  were  prescribed  only  in  the 
case of allergy confirmed by ii level investigations (prick 
test, nasal provocation test). oral corticosteroids (meth-
ylprednisolone, prednisone) were used, only seldomly, as 
adjunctive therapy to antibiotics (amoxicillin-clavulanic 
acid,  cefuroxime  axetil,  levofloxacin)  only  in  cases  of 
acute  episodes  of  rhinosinusitis  with  severe  symptoms 
(facial pain, headache).
As far as concerns lower airway disorders, when obstruc-
tion was diagnosed on the basis of symptoms (dyspnoae, 
secretion, cough) and functional tests (spirometry, metha-
choline test, Beta2 test), oral corticosteroids and/or aero-
sol treatment with corticosteroid, beta2 adrenergic and 
anti-cholinergic drugs were used; antibiotics and muco-
lytic agents were used only when an infectious disease 
was diagnosed.
All the subjects were re-evaluated 3 months after enroll-
ment.
A statistical analysis was performed using SPSS software; 
the significance index was evaluated using the χ2 Test.
Fig. 1. ENT and Pneumology centres involved in the study protocol on Rhi-
no-Bronchial-Syndrome.
Table I. Diagnostic approach.
I level examination
Clinical history
Infectious form suspected Immunologic form suspected
ENT & pneumologist ENT & pneumologist
Upper airway endoscopy Upper airway endoscopy
Respiratory functionality Respiratory functionality
Sputum bacteriology Sputum bacteriology
Mucociliary transport time Prick Test
Neutrophils count in nasal
secretion
Mucociliary transport time
Eosinophils count in nasal
secretion Chest X-rayD. Passali et al.
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Results
A total of 230 patients were recruited, of whom, only 159 
were considered valid for statistical analysis. of these, 
116 had a confirmed diagnosis of rBS, according to the 
“2003 Sio-AimAr Consensus report”. The 43 subjects, 
in whom the rBS diagnosis was not confirmed, were used 
as a control group.
Both allergic and infectious respiratory disorders were 
more  frequent  in  subjects  with  a  confirmed  diagnosis 
(Table iii). Specifically, an allergic sensitization was re-
corded in 37.9% of patients with a confirmed diagnosis 
of rBS compared with 20.9% in whom the diagnosis was 
not confirmed (p < 0.05). moreover, the percentage of rhi-
nosinusal infections, in the two groups, was: 73.3% (rBS 
Table III. Population data and clinical history.
Population Data RBS confirmed
(n = 116)
RBS not confirmed
(n = 43)
p
Age (yrs) (mean ± SD) 48.9 ± 13.1 45.5 ± 14.9
Sex no. (%)
   M 55 (47.4) 29 (67.4) 0.025
   F 61 (52.6) 14 (32.6)
Clinical history
Smoker no. (%)
   YES 32 (27.6) 10 (23.3) 0.065
   NO 57 (49.1) 15 (34.9)
   Ex 27 (23.3) 18 (41.9)
No. Sig./die (mean ± DS) 17.5 ± 10.6 10.4 ± 5.7 0.049
Alcohol no. (%)
   YES 63 (54.3) 27 (62.8) 0.338
   NO 53 (45.7) 16 (37.2)
Allergy no. (%)
   YES 44 (37.9) 9 (20.9)  0.04
   NO 72 (62.1) 34 (79.1)
Respiratory infections no. (%)
   No infection 13 (11.2) 7 (16.3)
   Rhinosinusitis 85 (73.3) 20 (46.5) 0.002
   Pharyngitis 76 (65.5) 16 (37.2) 0.000
   Bronchitis 81 (69.8) 15 (34.9) 0.001
  Head CT
          If suspected
  Rhinomanometry              Rhinosinusal chronic Inflammation, malformation, etc.
  Nasal provocation test           To evaluate nasal resistance, flows and pressure
 
  Chest CT            In case of suspected allergy with negative or doubtful Prick test
          If suspected
  Bronchoscopy              Pulmonary masses, Emphysema, Bronchiectasis, etc.
          Useful in difficult differential diagnosis for bal and brushing
Table II. Diagnostic approach.
II level examinationSio-AimAr survey on rhino-Bronchial Syndrome
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confirmed) and 46.5% (rBS not confirmed) (p = 0.002). 
Bronchial infections reached 69.8% when the rBS diag-
nosis was confirmed, compared with 34.9% of patients in 
whom diagnosis was not confirmed (p = 0.001).
The distribution of major symptoms is shown in Figure 2; 
as can be seen, some symptoms were more frequent in pa-
tients with confirmed rBS and specifically: nasal obstruc-
tion (93%, p < 0.03) rhinorrhoea (75%, p < 0.01), cough 
(96%, p < 0.001) and dyspnoea (69%, p < 0.002).
regarding  EnT  instrumental  examinations,  all  subjects 
underwent flexible (or rigid) rhino-endoscopy. Endoscop-
ic pictures are shown in Figure 3: briefly, the presence of 
meatal secretions (p < 0.05) and polyps (p < 0.05) were the 
clinical findings significantly differing in the two groups.
Concerning ii level examinations, imaging studies of the 
upper airways were frequently performed; namely, 116 
computed tomography (CT) skull-facial scans were per-
formed. At CT scan analysis, mucosal hypertrophy and 
complete obstruction of the ostio-meatal complex were 
more frequent in confirmed rBS patients than in the con-
trol group (p < 0.05) (Fig. 4). other ii level EnT tests, 
such  as  nasal  decongestion  test,  mucociliary  transport 
time, rhinomanometry were performed only in a few cas-
es with no significant effects on diagnostic accuracy.
Focusing on pneumological investigations, all the patients 
underwent basal spirometry, whereas a bronchoreversibil-
ity test with salbutamol was performed in 44 patients and 
the hyper-responsiveness test with methacholine in 12 pa-
tients; in a large number of patients, the diagnostic evalua-
tion was completed with chest X-ray (120 patients) or CT 
scan (27 patients) (Table iv).
in 116 patients with an anatomical or inflammatory altera-
tion or disease of the upper airways, pneumologists high-
lighted the following concomitant pathological conditions: 
chronic bronchitis (73 patients), obstructive chronic bron-
chitis (19 patients), asthma (43 patients), bronchiectasis 
(11 patients); in some of them, two or more of the above-
mentioned lower airways disorders coexisted.
The different treatment options selected by the various 
specialists involved in the study are reported in Table v. 
The  most  commonly  administered  drugs  were  inhaled 
steroids, either as bronchial or nasal (44%), antibiotics 
(42%), and nasal lavages (25.9%).
After 3 months of treatment, 73% of the sample (85 pa-
tients) was re-evaluated. in 94% of whom a significant 
improvement in the clinical picture was recorded, where-
as 6% of the patients remained unchanged.
Discussion
over the years, the scientific contributions revealing the 
association between rhinosinusal disorders and lower air-
Fig. 2. Distribution of major symptoms in patients with confirmed diagnosis.
Fig. 3. Endoscopic findings in 159 patients with confirmed/not confirmed 
RBS diagnosis.
Fig. 4. CT findings in patients with confirmed diagnosis and in control group 
(diagnosis not confirmed).D. Passali et al.
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ways diseases have definitively confirmed the interrela-
tion of the two districts and redefined the causative patho-
genetic mechanisms.
Concerning the rhinitis-asthma relationship, the reports 
from Braunstahl et al., analyzed, after nasal provocation 
with an allergen, the degree of infiltration of mucosal eosi-
nophils in a group of non-asthmatic subjects, affected by 
allergic rhinitis, compared to a control group; they showed 
an increased and significant infiltration of eosinophils in 
both the nasal and bronchial mucosa, independently of the 
district (nose or lung) exposed to the allergenic stimula-
tion 14 15. Similar results were obtained in studies focusing 
on the vascular expression of iCAm-1 16.
A report showing a correlation between CoPD (Chronic 
obstructive Pulmonary Disease) and upper airways inflam-
mation was presented by hurst et al., in 2005; they evaluated 
nasal and bronchial inflammation in patients with CoPD, by 
estimating the il-8 concentration (a cytokine with a well-
known chemotactic and activating effect on neutrophils), in 
comparison with a control group 17. A review on scientific 
evidence  supporting  the  link  between  non-allergic  upper 
airways disorders and asthma was made by Corren et al. 18: 
according to several studies most patients with non-allergic 
asthma have chronic nasal symptoms as well as radiographic 
evidence of sinus mucosal disease. Equally important, pre-
existing symptoms of rhinitis make non-allergic patients at 
higher risk of developing asthma. Systemic circulation plays 
a key role in amplifying inflammation in other portions of 
the respiratory tract.
According to Corren et al. 18, this significant body of lit-
erature on nose-lung correlations and the complex rela-
tionship  between  localized  and  systemic  inflammation, 
indicate that it is necessary to assess and treat rhinitis and 
sinusitis when they are present in patients with asthma. 
Common  diagnostic  criteria  and  treatment  protocols 
shared among a wide variety of practitioners, including 
otorhinolaryngologists,  pulmonologists,  primary  care 
physicians and allergologists will lead to a reduction in 
lower  airways  hyperesponsiveness,  improving  the  pa-
tients’ quality of life 19.
our results show, first of all, that chronic or recurrent up-
per airways infections (rhinosinusitis, pharyngitis) have a 
double prevalence in patients affected by rBS, that is why 
it is extremely important for the lower airways specialist, 
to investigate the clinical history of upper airways for a 
valid diagnostic approach.
Some prevalent symptoms, such as nasal obstruction, rhi-
norrhoea, dyspnoea, cough, must rise the suspicion of the 
entire respiratory tract involvement in the inflammatory 
process; they are, in fact, present in > 73% of patients 
with confirmed diagnosis of rhinobronchial syndrome.
Concerning the diagnostic approach, it is quite simple and 
can be standardized by the EnT specialist, as the gold 
standard test is flexible endoscopy of the rhinosinusal dis-
trict; the CT scan of this region, although not essential for 
the diagnosis, offers some interesting clinical data. A very 
recent study confirms the correlation between endoscopic 
scores and CoPD severity 19.
other ii level EnT tests, such as rhinomanometry and the 
nasal decongestion test, offer a good positive predictive 
Table IV. Pneumologic tests.
RBS 
confirmed
(n. 116)
RBS 
not confirmed
(n. 43)
FEV1/FVC
Obstruction 19 (17.6) 1 (2.4)
Normal 89 (82.4) 40 (97.6)
FEV1pc
Mild obstruction 83 (74.1) 38 (95.0)
Moderate obstruction 26 (23.2) 2 (5.0)
Severe obstruction 3 (2.7) –
Bronchoreversibility Test 31 (26.7) 13 (30.2)
Positive 12 (38.7) 1 (7.7)
Negative 19 (61.3) 12 (92.3)
Bronchostimulation 11 (9.5) 1 (2.3)
Positive 11 (100) –
Negative – 1 (100)
Chest X-ray 86 (74.1) 34 (79.1)
Positive 18 (20.9) –
Negative 68 (79.1) 34 (100)
Thorax CT 23 (19.8) 4 (9.3)
Positive 15 (65.2) 1 (25.0)
Negative 8 (34.8) 3 (75.0)
Prick- test  40 (34.5) 13 (30.2)
Monosensitization 12 (10.3) 3 (7.0)
Polysensitization 14 (12.1) 2 (4.7)
Negative 14 (12.1) 8 (18.5)
Not performed 76 (65.5) 30 (69.8)
Table V. Treatment in 116 patients with confirmed diagnosis of RBS.
Treatment  Number (%)
Nasal steroids 52 (44.8)
Antibiotic 49 (42.2)
Inhalatory steroids 35 (30.2)
Nasal lavages 30 (25.9)
Mucolitics 22 (19.0)
Systemic steroids 16 (13.8)
Beta2 stimulating 15 (12.9)
Anti-histamines 9 (7.8)
Anti-leukotrienes 7 (6.0)
No treatment 10 (8.6)Sio-AimAr survey on rhino-Bronchial Syndrome
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value but are not mandatory for diagnosis. on the contra-
ry, the pneumological evaluation is more complicated as 
clinical data, pulmonary functionality tests and imaging 
have to be integrated to make a correct diagnosis.
interestingly, according to our results, as soon as rBS 
is correctly diagnosed, the therapeutic approach is not a 
problem, as revealed by a 3 months recovery rate of about 
94% of the sample.
Nasal obstruction
and/or
Nasal discharge
with Cough
and/or
Dyspnoea
Family physician
no
ENT or Pneumologist
ENT Pneumologist
Clinical examination,
Endoscopy ± nose-sinuses CT
Clinical examination,
beta2 test, methacoline test,
spirometry, Chest x-ray, Chest CT
if
Clinical pulmonary finding:
Recurrent bronchitis
Symptoms:dyspnea and cough
Clinical ENT findings:
Rhinosinusitis, pharyngitis
Symptoms: cough, nasal obstruction,
rhinorrhoea
Pneumologist ENT
If confirmed
RBS
if
yes
Therapy
Recovery
Fig. 5. Integrated multidisciplinary diagnostic flow chart.D. Passali et al.
34
in  conclusion,  we  propose  a  diagnostic  flow-chart  in 
which some symptoms, such as cough, dyspnoea, rhin-
orrhoea and nasal obstruction, if not completely recov-
ered after the initial treatment by the general practitioner, 
should lead the patient to seek an EnT and pneumologi-
cal evaluation for a definitive diagnosis and treatment. in 
turn, these two specialists have to cooperate in order to 
guarantee a multidisciplinary and multi-level diagnostic 
approach for any patient with a rhinobronchial syndrome 
not yet confirmed.
in particular, the EnT specialist, after having carefully 
evaluated the upper airways by means of fiberoptic endos-
copy, should investigate, in these patients, the possibil-
ity of recurrent bronchitis or other lower airways-related 
problems and where necessary, referring the patient for 
pneumological  evaluation.  likewise,  the  pneumologist 
should  refer,  to  the  EnT  colleague,  any  asthmatic  or 
CoPD patient with a positive clinical history for rhinosi-
nusitis or pharyngitis or complaining of chronic nasal ob-
struction (Fig. 5).
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